Orandbio’s Innovations in Renal Health Technology

Orandbio has made notable strides in developing solutions for renal health, emphasizing its dedication to advancing medical technology. This Korean company recently gained attention after being selected for the “Deep Tech TIPS” program aimed at accelerating research and development in medical devices.

Deep Tech TIPS Selection

Orandbio, a specialist in bio-material based medical devices, has been selected for the “Deep Tech TIPS” program under the Ministry of Small and Medium Enterprises and Startups. This selection method:

• Provides a three-year government R&D grant totaling 1.5 billion KRW.
• Facilitates the development of advanced renal function recovery medical devices.

The focus is on innovative kidney function recovery medical equipment that addresses limitations of traditional treatments like dialysis and kidney transplants.

Chronic Kidney Disease (CKD) Challenges

CKD remains a significant health concern, affecting an estimated 10% of adults globally. This reality underscores the importance of developing early intervention techniques:

• CKD treatment costs often surpass those for cancer and dementia.
• Early intervention can delay or replace the need for dialysis or transplants.

Orandbio aims to introduce new treatment solutions for CKD patients, potentially transforming how the condition is managed.

CharmRenal: A New Approach

Orandbio’s CharmRenal device highlights a promising bio-material application, incorporating biodegradable polymers to foster kidney tissue regeneration:

• Shows potential in small animal trials, achieving a kidney function recovery of up to 50%.
• Aims to replicate these results in larger, human-scale applications.

Expanding CharmRenal for both pets and humans capitalizes on fast-growing demand, particularly for aging pets where kidney disease is a leading cause of death.

Future Plans and Global Strategy

Looking ahead, Orandbio plans to tackle several key areas:

1. Preclinical and Clinical Stages:

   • Develop preclinical programs for pet products.
   • Prepare for clinical trials of human applications.

2. Manufacturing and Regulation:

   • Establish GLP-based preclinical and GMP manufacturing technologies.
   • Navigate regulatory approvals (FDA, MDR/CE) for global market entry.

3. Product Launch Goals:

   • Pet products are anticipated by 2029 domestically and 2031 internationally.
   • Human-targeted products are anticipated post-2031.

Broader Medical Device Portfolio

Beyond renal health, Orandbio expands into other medical domains, striving to diversify its high-performance medical device portfolio:

• Develops bioactive osteoarthritis treatments.
• Offers advanced bone graft materials.
• Innovates periodontal tissue regenerative materials.

The company’s initiatives demonstrate a robust commitment to addressing diverse medical needs through cutting-edge technology.

Investor and Market Sentiments

Investors and market analysts view Orandbio’s approach and technology with optimism. Zenexis, an accelerator and Orandbio’s selector for the TIPS program, sees noteworthy potential in surpassing current treatment frameworks. As Orandbio enhances its capabilities in biological scaffolds and regenerative medicine:

• It aims for significant achievements in the global market.
• Innovation continues to play a pivotal role in shaping future treatment landscapes.

Conclusion

Orandbio’s progress in renal health technologies points to a bright future in medical innovation. By focusing on early intervention and high-performance treatments, the company hopes to transform CKD management and extend its impact across various medical fields. For anyone interested in medical technology advancements, Orandbio represents a compelling journey towards innovative healthcare solutions.